January 1, 2011
As a subsidiary of Mensa Group, Otto is a pharmaceutical manufacturing company which produces various high quality pharmaceutical with the aim to serve Indonesian health society. Therefore, good manufacturing practice standard (GMP) and international standards (PIC/S) are important requirements. Currently, we have a production unit for non betalactam, penicillin, and cephalosporin.
With a commitment to grow, we made new investment by setting up a new factory in Lembang, Bandung with new production facility for tablets, capsules, syrup, dry syrup, creams, sachets of oral and injectable products. We invested approximately US$ 28 million and appointed a world class pharmaceutical manufacturing construction consultant JJ Pharmaplan to design the new plant which is scheduled to be completed at the end of 2011 by combining the latest cGMP standards and best concept for a new formulation facility.
Later, this new formulation plant will have two separate buildings with manufacturing facilities for:
- Non Betalactam Group for Non-sterile Therapeutically Drugs & Injectable Oral Solution
- Cephalosporin Group for Non-sterile Therapeutically Drugs & Injectable Oral Powder
OUR PRODUCT: CONTINUOUS INNOVATION
We have the philosophy that every drug produced must have a good quality starting from selecting the raw materials, production process, and packaging always bearing in mind that every drug is for human consumption. With a fairly complex set of products, including generic and non generic, our marketing division covers the entire territory of Indonesia and also some overseas countries such as Singapore, Malaysia, Sudan, Myanmar, Hong Kong, Cambodia, Sri Lanka, and Vietnam.
In addition, we also continue to innovate by following the trends that allow us to move forward accelerating in the market. To complete the portfolio of businesses that are owned at this time, we also entered the osteoporosis business in March 2006 by launching Hi-Bone products as bone and joint supplement containing 300mg of calcium phosphate. Seeing the business trend of osteoporosis, we also launched related product namely Hi-Bone 600 containing extra calcium (calcium phosphate, calcium carbonate 300mg and 300mg) in July 2010
OUR SALES FORCE
To win the health market competition in Indonesia, we realized the quality of drug and competent force are the main determining factor. In support to this we regularly organize in house training in the attempt to develop the competence of the entire sales force.